437 related articles for article (PubMed ID: 36971965)
1. HER2-Low Breast Cancer: a New Subtype?
Corti C; Giugliano F; Nicolò E; Tarantino P; Criscitiello C; Curigliano G
Curr Treat Options Oncol; 2023 May; 24(5):468-478. PubMed ID: 36971965
[TBL] [Abstract][Full Text] [Related]
2. The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan.
Schreiber AR; O'Bryant CL; Kabos P; Diamond JR
Expert Rev Anticancer Ther; 2023; 23(10):1061-1069. PubMed ID: 37742278
[TBL] [Abstract][Full Text] [Related]
3. Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.
Adams E; Wildiers H; Neven P; Punie K
ESMO Open; 2021 Aug; 6(4):100204. PubMed ID: 34225076
[TBL] [Abstract][Full Text] [Related]
4. HER2-Low Breast Cancer-Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast.
Bardia A; Viale G
Target Oncol; 2023 May; 18(3):313-319. PubMed ID: 37133651
[TBL] [Abstract][Full Text] [Related]
5. The HER2-low revolution in breast oncology: steps forward and emerging challenges.
Nicolò E; Boscolo Bielo L; Curigliano G; Tarantino P
Ther Adv Med Oncol; 2023; 15():17588359231152842. PubMed ID: 36844387
[TBL] [Abstract][Full Text] [Related]
6. Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles.
Fenton MA; Tarantino P; Graff SL
Curr Oncol; 2023 Nov; 30(12):10211-10223. PubMed ID: 38132377
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04.
Zhan M; Huang Z; Xu T; Xu X; Zheng H; Wu F
Front Public Health; 2023; 11():1049947. PubMed ID: 37457280
[TBL] [Abstract][Full Text] [Related]
8. Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer.
Curigliano G; Dent R; Earle H; Modi S; Tarantino P; Viale G; Tolaney SM
ESMO Open; 2024 Apr; 9(4):102989. PubMed ID: 38613914
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer.
Shi D; Liang X; Li Y; Chen L
PLoS One; 2023; 18(8):e0290507. PubMed ID: 37616309
[TBL] [Abstract][Full Text] [Related]
10. HER2-low expression in breast oncology: treatment implications in the smart chemotherapy era.
Giugliano F; Curigliano G; Tarantino P
Eur J Cancer Prev; 2023 Mar; 32(2):149-154. PubMed ID: 36693209
[TBL] [Abstract][Full Text] [Related]
11. How I treat HER2-low advanced breast cancer.
Schlam I; Tolaney SM; Tarantino P
Breast; 2023 Feb; 67():116-123. PubMed ID: 36669993
[TBL] [Abstract][Full Text] [Related]
12. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer.
Shastry M; Jacob S; Rugo HS; Hamilton E
Breast; 2022 Dec; 66():169-177. PubMed ID: 36302269
[TBL] [Abstract][Full Text] [Related]
13. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.
Dent RA; Cescon DW; Bachelot T; Jung KH; Shao ZM; Saji S; Traina TA; Vukovic P; Mapiye D; Maxwell MJ; Schmid P; Cortés J
Future Oncol; 2023 Nov; 19(35):2349-2359. PubMed ID: 37526149
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness and Value-based Pricing of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Low HER2 Expression.
Huang X; Lin D; Lin S; Luo S; Huang X; Deng Y; Weng X; Huang P
Clin Breast Cancer; 2023 Jul; 23(5):508-518. PubMed ID: 37085377
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study.
Modi S
Future Oncol; 2021 Sep; 17(26):3415-3423. PubMed ID: 34263665
[TBL] [Abstract][Full Text] [Related]
16. TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer.
Bardia A; Jhaveri K; Kalinsky K; Pernas S; Tsurutani J; Xu B; Hamilton E; Im SA; Nowecki Z; Sohn J; Laurentiis M; Jañez NM; Adamo B; Lee KS; Jung KH; Rubovszky G; Tseng LM; Lu YS; Yuan Y; Maxwell MJ; Haddad V; Khan SS; Rugo HS; Pistilli B
Future Oncol; 2024 Mar; 20(8):423-436. PubMed ID: 37387213
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab deruxtecan for HER2+ advanced breast cancer.
Lee J; Park YH
Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373
[TBL] [Abstract][Full Text] [Related]
18. Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer.
Rugo HS; Crossno CL; Gesthalter YB; Kelley K; Moore HB; Rimawi MF; Westbrook KE; Buys SS
JCO Oncol Pract; 2023 Aug; 19(8):539-546. PubMed ID: 37207306
[TBL] [Abstract][Full Text] [Related]
19. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer.
von Arx C; De Placido P; Caltavituro A; Di Rienzo R; Buonaiuto R; De Laurentiis M; Arpino G; Puglisi F; Giuliano M; Del Mastro L
Cancer Treat Rev; 2023 Feb; 113():102500. PubMed ID: 36587473
[TBL] [Abstract][Full Text] [Related]
20. Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure.
Antonarelli G; Corti C; Tarantino P; Salimbeni BT; Zagami P; Marra A; Trapani D; Tolaney S; Cortes J; Curigliano G
ESMO Open; 2023 Aug; 8(4):101608. PubMed ID: 37467660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]